Preoperative systemic inflammatory markers as prognostic factors in differentiated thyroid cancer : a systematic review and meta-analysis
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
BACKGROUND: Inflammation has been associated with tumor development and circulating inflammatory biomarkers have been proposed as possible predictors of recurrence of several solid tumors. However, the role of inflammation markers in differentiated thyroid carcinoma (DTC) is still uncertain.
OBJECTIVE: This meta-analysis aimed to assess the prognostic value of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) in patients with DTC.
METHODS: Studies investigating the association between survival and preoperative circulating inflammatory markers in DTC patients were included. The primary outcome was disease-free survival (DFS). Cumulative logarithms of the hazard ratio (log-HRs) with 95% CI were calculated through the inverse variance method using a random-effects model.
RESULTS: A total of 7599 patients with a mean age of 48.89 (95% CI 44.16-53.63) were included. The estimated pooled log-HRs for DFS were 0.07 for NLR (95% CI -0.12-0.26; p = 0.43), -0.58 for LMR (95% CI -1.21-0.05; p = 0.06), and 0.01 (95% CI 0-0.01; p = 0.21) for PLR.
CONCLUSIONS: Our meta-analysis showed no association between NLR, PLR, LMR and DFS in DTC; however, more prospective data are needed to better define the association between inflammatory status and prognosis of DTC.
| Errataetall: |
ErratumIn: Rev Endocr Metab Disord. 2023 Nov 18;:. - PMID 37979073 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Reviews in endocrine & metabolic disorders - 24(2023), 6 vom: 10. Dez., Seite 1205-1216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Russo, Elena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Differentiated thyroid carcinoma |
|---|
| Anmerkungen: |
Date Completed 06.12.2023 Date Revised 15.03.2024 published: Print-Electronic ErratumIn: Rev Endocr Metab Disord. 2023 Nov 18;:. - PMID 37979073 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11154-023-09845-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363213554 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363213554 | ||
| 003 | DE-627 | ||
| 005 | 20240315232812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11154-023-09845-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM363213554 | ||
| 035 | |a (NLM)37828383 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Russo, Elena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preoperative systemic inflammatory markers as prognostic factors in differentiated thyroid cancer |b a systematic review and meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2023 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Rev Endocr Metab Disord. 2023 Nov 18;:. - PMID 37979073 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a BACKGROUND: Inflammation has been associated with tumor development and circulating inflammatory biomarkers have been proposed as possible predictors of recurrence of several solid tumors. However, the role of inflammation markers in differentiated thyroid carcinoma (DTC) is still uncertain | ||
| 520 | |a OBJECTIVE: This meta-analysis aimed to assess the prognostic value of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) in patients with DTC | ||
| 520 | |a METHODS: Studies investigating the association between survival and preoperative circulating inflammatory markers in DTC patients were included. The primary outcome was disease-free survival (DFS). Cumulative logarithms of the hazard ratio (log-HRs) with 95% CI were calculated through the inverse variance method using a random-effects model | ||
| 520 | |a RESULTS: A total of 7599 patients with a mean age of 48.89 (95% CI 44.16-53.63) were included. The estimated pooled log-HRs for DFS were 0.07 for NLR (95% CI -0.12-0.26; p = 0.43), -0.58 for LMR (95% CI -1.21-0.05; p = 0.06), and 0.01 (95% CI 0-0.01; p = 0.21) for PLR | ||
| 520 | |a CONCLUSIONS: Our meta-analysis showed no association between NLR, PLR, LMR and DFS in DTC; however, more prospective data are needed to better define the association between inflammatory status and prognosis of DTC | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Differentiated thyroid carcinoma | |
| 650 | 4 | |a Lymphocyte-to-monocyte ratio | |
| 650 | 4 | |a Neutrophil-to-lymphocyte ratio | |
| 650 | 4 | |a Platelet-to-lymphocyte ratio | |
| 650 | 4 | |a Prognostic factor | |
| 700 | 1 | |a Guizzardi, Mathilda |e verfasserin |4 aut | |
| 700 | 1 | |a Canali, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Gaino, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Costantino, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Mazziotti, Gherardo |e verfasserin |4 aut | |
| 700 | 1 | |a Lania, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Uccella, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Di Tommaso, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreli, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Malvezzi, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Spriano, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Mercante, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews in endocrine & metabolic disorders |d 2000 |g 24(2023), 6 vom: 10. Dez., Seite 1205-1216 |w (DE-627)NLM115974520 |x 1573-2606 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:6 |g day:10 |g month:12 |g pages:1205-1216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11154-023-09845-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 6 |b 10 |c 12 |h 1205-1216 | ||